83 related articles for article (PubMed ID: 10366688)
1. Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice.
Cleren C; Vilpoux C; Dourmap N; Bonnet JJ; Costentin J
Brain Res; 1999 Jun; 830(2):314-9. PubMed ID: 10366688
[TBL] [Abstract][Full Text] [Related]
2. Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.
Cleren C; Naudin B; Costentin J
Brain Res; 2003 Nov; 989(2):187-95. PubMed ID: 14556940
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Staal RG; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
5. Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice.
Naudin B; Bonnet JJ; Costentin J
Brain Res; 1995 Dec; 701(1-2):151-7. PubMed ID: 8925278
[TBL] [Abstract][Full Text] [Related]
6. L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.
Reveron ME; Savelieva KV; Tillerson JL; McCormack AL; Di Monte DA; Miller GW
Neurotoxicology; 2002 Oct; 23(4-5):611-9. PubMed ID: 12428733
[TBL] [Abstract][Full Text] [Related]
7. Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Staal RG; Yang JM; Hait WN; Sonsalla PK
Brain Res; 2001 Aug; 910(1-2):116-25. PubMed ID: 11489261
[TBL] [Abstract][Full Text] [Related]
8. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.
Speciale SG; Liang CL; Sonsalla PK; Edwards RH; German DC
Neuroscience; 1998 Jun; 84(4):1177-85. PubMed ID: 9578404
[TBL] [Abstract][Full Text] [Related]
9. Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats.
Espino A; Cutillas B; Tortosa A; Ferrer I; Bartrons R; Ambrosio S
Brain Res; 1995 Oct; 695(2):151-7. PubMed ID: 8556325
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models.
Ito Y; Fujita M; Shimada S; Watanabe Y; Okada T; Kusuoka H; Tohyama M; Nishimura T
Synapse; 1999 Mar; 31(3):178-85. PubMed ID: 10029235
[TBL] [Abstract][Full Text] [Related]
11. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice.
Gainetdinov RR; Fumagalli F; Wang YM; Jones SR; Levey AI; Miller GW; Caron MG
J Neurochem; 1998 May; 70(5):1973-8. PubMed ID: 9572281
[TBL] [Abstract][Full Text] [Related]
12. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity.
Van Kampen JM; McGeer EG; Stoessl AJ
Synapse; 2000 Sep; 37(3):171-8. PubMed ID: 10881039
[TBL] [Abstract][Full Text] [Related]
13. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
14. Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells.
Chen CX; Huang SY; Zhang L; Liu YJ
Neurobiol Dis; 2005 Aug; 19(3):419-26. PubMed ID: 16023584
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of the hypothermic effect of MPP+ administered centrally in mice.
Drouet I; Suaudeau C; Dourmap N; Costentin J
Neuropharmacology; 1997 Jul; 36(7):993-7. PubMed ID: 9257943
[TBL] [Abstract][Full Text] [Related]
16. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
17. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
18. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).
Numis AL; Unger EL; Sheridan DL; Chisnell AC; Andrews AM
Mol Pharmacol; 2004 Sep; 66(3):718-27. PubMed ID: 15322265
[TBL] [Abstract][Full Text] [Related]
19. The neurotoxin 1-methyl-4-phenylpyridinium is a substrate for the canalicular organic cation/H+ exchanger.
Moseley RH; Zugger LJ; Van Dyke RW
J Pharmacol Exp Ther; 1997 Apr; 281(1):34-40. PubMed ID: 9103477
[TBL] [Abstract][Full Text] [Related]
20. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
